NGM Biopharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NGM research report →
Range $4 – $29
Price Chart
About the company
NGM Biopharmaceuticals, Inc. is a biotechnology company focused on discovering and developing innovative therapies for liver and metabolic ailments, retinal conditions, and various forms of cancer. The company's advanced product candidates include Aldafermin, a modified version of the human hormone fibroblast growth factor 19, which is currently undergoing Phase IIb clinical evaluation for non-alcoholic steatohepatitis (NASH).
- CEO
- David J. Woodhouse
- IPO
- 2019
- Employees
- 138
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on NGM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $128.53M
- P/E
- -0.89
- PEG
- -0.06
- P/S
- 29.10
- P/B
- 0.85
- EV/EBITDA
- -0.48
- Div Yield
- 0.00%
- Gross Margin
- 49.72%
- Op Margin
- -3317.79%
- Net Margin
- -3223.34%
- ROE
- -69.76%
- ROIC
- -98.49%
Latest fiscal year · YoY change
- Revenue
- $4.42M-92.0%
- Gross Profit
- $2.20M-95.6%
- Op Income
- $-146,547,000
- Net Income
- $-142,375,000+10.5%
- EPS
- $-1.73+13.1%
- OCF Growth
- +8.5%
- FCF Growth
- +8.8%
- 52W High
- $4.69
- 52W Low
- $0.60
- 50D MA
- $1.55
- 200D MA
- $1.49
- Beta
- 1.26
- RSI (14)
- 49
- Avg Volume
- 1.07M
No earnings-call transcripts are available for NGM yet.
- Free Float
- 34.6%
- Shares Outstanding
- 83.46M
- Float Shares
- 28.89M
of shares held by institutions
83 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cutler Group LLC / Ca | 3.10K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 5, 24 | TCG Opportunity III GP, LLC | other | 1,000 |
| Apr 5, 24 | TCG Opportunity III GP, LLC | sell | 44,000 |
| Apr 5, 24 | COLUMN GROUP GP, LP | other | 1,000 |
| Apr 5, 24 | COLUMN GROUP GP, LP | sell | 44,000 |
| Apr 5, 24 | COLUMN GROUP L P | other | 1,000 |
| Apr 5, 24 | COLUMN GROUP L P | sell | 44,000 |
| Apr 5, 24 | GOEDDEL DAVID V | other | 1,000 |
| Apr 5, 24 | GOEDDEL DAVID V | sell | 100,000 |
| Apr 5, 24 | GOEDDEL DAVID V | sell | 24,000 |
| Apr 5, 24 | GOEDDEL DAVID V | sell | 19,619 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NGM coverage
Recent articles, reports, and earnings notes.
No research on NGM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NGM report →Quaise Energy and Nevada Gold Mines Partner on Deep Geothermal Pilot Plant to Decarbonize Mining
businesswire.com · Dec 3
NGM Bio Announces Closing of Tender Offer
globenewswire.com · Apr 5
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
accesswire.com · Mar 21
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
accesswire.com · Mar 20
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
globenewswire.com · Mar 19
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
accesswire.com · Mar 19
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm
accesswire.com · Mar 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.